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Abstract
Introduction: Over the past decade, preeclampsia has been the subject of an increased attention, as this complication 
is the most common cause of maternal mortality, triggering every third case of obstetric morbidity and taking lives of 
up to 50.000 young women worldwide each year. Despite a large number of ongoing studies, no clear algorithm for 
monitoring pregnant women with this pathology has been developed yet.
Materials and methods: The study was conducted on 220 female Wistar rats weighing 250–300 g. In the experiment, 
ADMA-like preeclampsia model was used.
Results and discussion: The introduction of L-NAME to the animals from the 14th till the 20th day of pregnancy causes 
the following disturbances: a rise in systolic and diastolic blood pressure in 1.4 and 1.5 times, an increase in proteinuria 
in 3.3 times and an increase in the content of fluid in the greater omentum from 44.39 ± 1.62% to 55.02 ± 1.74%, all of 
which correspond to the disorders in pregnant women in case of preeclampsia.
The use of the selective inhibitor of arginase II KUD 975 (3mg/kg/day) in combination with acetylsalicylic acid (10mg/
kg/day) leads to a pronounced correction in the emerging changes: a decrease in systolic and diastolic blood pressure 
in 1.2 and 1.3 times, a decrease in proteinuria in 1.9 times and a decrease in the fluid content in the greater omentum.
Conclusion: Selective inhibitor of arginase II KUD 975 and small doses of acetylsalicylic acid have a pronounced 
positive effect in the correction of morphofunctional disorders in animals with ADMA-like preeclampsia.
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Introduction
Preeclampsia, being the most frequent cause in the struc-
ture of maternal mortality over the past decade, has been 
the object of increased attention, as this complication cau-
ses every 3rd case of obstetric morbidity and annually ta-
kes up to 50.000 lives of young women around the world 
(Adamyan et al. 2016, Shakhno et al. 2016, Yakushev et 
al. 2016). Perinatal mortality rates and the rate of preterm 
birth (10–12%) in pregnant women with hypertensive di-
sorders largely prevail over the corresponding values in 
women with physiological pregnancy. The incidence of 
preeclampsia during pregnancy ranges from 2 to 8% (Gu-
reev et al. 2014, Gureev et al. 2015). Despite such close 
attention to this problem worldwide, the number of cases 
of this complication does not tend to decrease (Korokin et 
al. 2015). In recent years, the number of studies indicating 
that the main role in the development of preeclampsia is 
played by a violation of the functional state of the vascu-
lar endothelium, which entails the development of a ge-
neralized spasm, increased blood pressure and, as a con-
sequence, ischemic disorders in the organs. In addition, 
especially dangerous and attracting an increased attention 
are disturbances in the hemostatic system in preeclampsia 
(AlSheeha et al. 2016, Severinova et al. 2019).
One of the main tasks of modern pharmacology and 
clinical pharmacology is the search for new drugs for the 
correction of various pathological conditions (Elagin et 
al. 2018, Skachilova et al. 2018), including preeclamp-
sia (Gureev et al. 2014, Gureev et al. 2015). Despite a 
huge number of ongoing studies aimed at examining the 
etiopathogenetic aspects of preeclampsia, possible me-
thods of drug and non-drug prevention and correction of 
this complication of pregnancy, no clear algorithm for the 
management of pregnant women with this pathology has 
been developed yet. The only effective method of treat-
ment for this condition is a delivery, the purpose of which 
is primarily to minimize the threat to the life of a pregnant 
woman. Modern methods of treatment and prevention of 
preeclampsia, used in the daily practice of obstetricians 
and gynecologists, are aimed primarily at correcting the 
dominant syndrome itself, without sufficient considerati-
on of the pathogenetic component. At the same time, it 
should be noted that in the modern literature there is in-
formation about experimental papers on different approa-
ches of correction of simulated preeclampsia. Among the 
patho-physiologically sound approaches used in them are 
the methods aimed at: correction of placental ischemia 
using drugs that improve the depth of placentation and 
blood flow in the spiral arteries of the uterus (Tyurenkov 
et al. 2012, Rodger et al. 2014, Khodzhaeva et al. 2018), 
as well as the use of remote ischemic preconditioning and 
pharmacological preconditioning as activators of natural 
cytoprotection processes (Xu et al. 2017), improvement 
of impaired endothelial function and restoration of eNOS 
activity (Yakushev et al. 2012, Khodzhaeva et al. 2018), 
correction of hemostatic system (Roberge et al. 2012, 
Khodzhaeva et al. 2018), elimination of of oxidative stress 
manifestations (Memmert et al. 2016), correction of ba-
lance of cytokines and other humoral factors (Makarenko 
2014, Saito et al. 2007). Arginase inhibitors are a promi-
sing group of drugs for the treatment of hypertensive con-
ditions in pregnant women. Currently, there are a lot of 
data about their pronounced endothelioprotective proper-
ties obtained on different experimental models (Pokrovs-
kiy et al. 2012, Yakushev et al. 2012). Arginase II inhi-
bitors are of particular interest as they are more selective.
Recently, in the literature there has been evidence that 
disturbances in the hemostatic system can be not only a 
complication of preeclampsia or develop alongside it, but 
can also precede its manifestation or, to some extent, con-
tribute to its development. The pathogenetic events that 
explain the role of activated platelets in the development 
of endothelial dysfunction in various diseases, including 
preeclampsia, are described in (Sidorenko et al. 2007, 
Hussien and Emam 2016, Blomqvist et al. 2019, Severi-
nova et al. 2019).
The above call for search for and study the efficacy of 
new and currently available drugs aimed at the preventi-
on and treatment of preeclampsia and its complications. 
Considering the fact that preeclampsia is based on a viola-
tion of the normal course of the placentation process with 
incomplete remodeling of the spiral arteries, resulting in 
placental ischemia and subsequent microcirculation di-
sorders, inflammation, hemostatic disorders, oxidative 
stress and endothelial dysfunction, followed by an imba-
lance between vasoconstrictors and vasodilators (Hussien 
and 2016), the most promising direction in the treatment 
and prevention of preeclampsia is a combination of drugs 
that can stop the various above-mentioned pathogenetic 
aspects of this pathological condition during pregnancy.
Materials and methods
The research was conducted on 220 female Wistar rats 
weighing 250–300 g. The experimental study was conduc-
ted at the Research Institute of Pharmacology of Living 
Systems of Belgorod State National Research University. 
The study was performed in compliance with the requi-
rements of General Requirements for the Competence of 
Testing and Calibration Laboratories 17025-2009, GOST 
R ISO 5725-2002 and the Rules of Laboratory Practice, 
approved by Order of the Ministry of Healthcare and So-
cial Development of the Russian Federation dated August 
23rd, 2010 № 708n, in compliance with the European Con-
vention for the Protection of Vertebrates Used for Expe-
riments or Other Scientific Purposes [Directive 2010/63/
EU]. All the experiments were approved by the Ethical 
Committee of Belgorod National Research University. 
Vivisection was performed in compliance with the ethi-
cal principles of treating laboratory animals in European 
Convention for the Protection of Vertebrates Used for Ex-
perimental and Other Scientific Purposes. CETS No. 123.
The experimental animals were kept in individually ven-
tilated cells “Tecniplast” for small laboratory animals. Bed-
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ding was made of sawdust sterilized under UV irradiation. 
The animals were fed with granulated feedstuff for small la-
boratory animals-rodents. Water was purified and sterilized 
by UV irradiation. The microclimate was created and main-
tained by a system of individually ventilated cells. Acclima-
tization and selection of animals for research consisted of a 
quarantine for at least 10 days. The animals were divided 
into groups according to their body weight. The animal were 
identified by applying individual labels on their bodies.
At the time of the research, the animals were healthy, 
without any changes in behavior, appetite, sleep and wake-
fulness. For 18 h before the experiments, the animals had 
been completely deprived of food, with free access to water.
In order to form groups of pregnant animals, males (2 
animals), which had been kept separately, were put into 
cages to females (3 animals) for a day. Then the animals 
were separated again, and 10–14 days later, in a drug-in-
duced sleep, by palpating the anterior abdominal wall, the 
fact of pregnancy was established. The pregnant rats were 
then randomized into 11 groups:
• Group 1 – intact (animals with physiological preg-
nancy);
• Group 2 – control (simulation of ADMA-like pre-
eclampsia in the studied animals was performed by 
administration of a nonselective NOS blocker N-ni-
tro-L-arginine-methyl ether (L-NAME) 25 mg/kg/
day intraperitoneally from the 14th to the 20th day of 
pregnancy);
• Group 3 – L-NAME + L-Norvaline at a dose of 
10 mg/kg/day orally from the 14th to the 20th day of 
pregnancy;
• Group 4 – L-NAME + methyldopa at a dose of 
0.043 g/kg/day twice a day orally from the 14th to 
the 20th day of pregnancy;
• Group 5 – L-NAME + selective inhibitor of argi-
nase II, KUD 975, at a dose of 1 mg/kg/day orally 
from the 14th to the 20th day of pregnancy;
• Group 6 – L-NAME + selective inhibitor of argi-
nase II, KUD 975, at a dose of 3 mg/kg/day orally 
from the 14th to the 20th day of pregnancy;
• Group 7 – L-NAME + acetylsalicylic acid (ASA) at 
a dose of 7 mg/kg/day orally from the 14th to the 20th 
day of pregnancy;
• Group 8 – L-NAME + acetylsalicylic acid at a dose 
of 10 mg/kg/day orally from the 14th to the 20th day 
of pregnancy;
• Group 9 – L-NAME + selective inhibitor of argin-
ase II, KUD 975, at a dose of 3 mg/kg/day orally + 
acetylsalicylic acid at a dose of 10 mg/kg/day orally 
from the 14th to the 20th day of pregnancy;
• Group 10 – L-NAME + acetylsalicylic acid at a 
dose of 10 mg/kg/day + methyldopa at a dose of 
0.043 g/kg/day twice a day orally from the 14th to 
the 20th days of pregnancy;
• Group 11 – L-NAME + KUD 975 at a dose of 3 mg/
kg/day + methyldopa at a dose of 0.043 g/kg/day twice 
a day orally from the 14th to the 20th day of pregnancy.
On the 21st day of the gestation, the experimental 
animal was anesthetized by intraperitoneal injection of 
chloral hydrate at a dose of 300 mg/kg of body weight, 
after which the functional tests were performed.
The hemodynamic parameters registered, and then the 
study of the endothelial function was carried out by means 
of a sensor and a hardware complex for invasive measu-
rement of hemodynamic parameters Biopac (USA) and 
computer software ACQKNOWLEDGE 3.8.1. To evalu-
ate the functional state of the endothelium, a calculated 
index was used – the coefficient of endothelial dysfunc-
tion (CED), which is the ratio of endothelium-dependent 
vasorelaxation (acetylcholine) and endothelium-indepen-
dent vasorelaxation (sodium nitroprusside).
The final level of NO metabolites (total concentration 
of nitrate and nitrite, NOx) in blood plasma of the studied 
animals was measured using a colorimetric method by 
evaluating the development of staining in the reaction of 
diazotization by sulfanilamide nitrite.
The evaluation of the microcirculation state in the pla-
centa was carried out using equipment from Biopac sys-
tems: a MP100polygraph with a laser Doppler flowmetry 
module (LDM) LDF100C and an invasive needle sensor 
TSD144, which was placed directly on the projection of 
the placental disc. Registration and processing of LDM 
results were performed using AcqKnowledge version 
3.8.1; the microcirculation values were expressed in per-
fusion units (PU).
Collection of daily urine was carried out in metabolic 
cages. Evaluation of protein level in daily urine was car-
ried out by the pyrogallol method on spectrophotometer 
PE-5400 V.
Descriptive statistics was applied to all the data: the 
data were checked for normality of distribution. The 
type of distribution was determined by the Shapiro-Wilk 
criterion. In the case of normal distribution, the mean 
(M) and the standard error of the mean (m) were cal-
culated. The ontergroup differences were analyzed by 
methods depending on a type of distribution (Student’s 
t-test or Mann-Whitney test). All the calculations were 
performed using a statistical software package Micro-
soft Excel 2010.
Results and discussion
Experimental study of the effect of selective 
inhibitor of arginase II KUD 975 and low doses of 
acetylsalicylic acid on functional disorders in ADMA-
like preeclampsia
The simulation of ADMA-like preeclampsia resulted in 
an increase in systolic and diastolic blood pressure from 
127.6±1.5 mmHg and 91.9±5.63 mmHg up to 200.5±6.32 
mmHg and 151±5.69 mmHg, respectively. There was a 
distortion of the ratio of endothelium-dependent and en-
dothelium-independent vasorelaxations, which resulted in 
an increase in CED from 1.32±0.8% c.u. to 3.13±0.21 c.u. 
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There was a decrease in microcirculation in the placenta 
from 487.9±22.56 PU to 210.2±11.18 PU.
The introduction of selective inhibitor of arginase II 
KUD 975 at a dose of 3 mg/kg/day in rats with expe-
rimental preeclampsia led to a statistically significant 
(p<0.05) decrease in systolic and diastolic blood pres-
sure to 167.4±4.84 mmHg and 126.6 ± 4.85 mmHg, 
respectively. The introduction of selective inhibitor of 
arginase II KUD 975 at a dose of 1 mg/kg/day, as well 
as the introduction of acetylsalicylic acid at doses of 7 
mg/kg/day and 10 mg/kg/day in rats with experimental 
preeclampsia did not lead to a statistically significant 
(p<0.05) decrease in systolic and diastolic blood pres-
sure (Table 1).
The ratio of endothelium-dependent vasorelaxation 
and endothelium-independent vasorelaxation, expressed 
by СED, selective inhibitor of arginase II KUD 975 and 
acetylsalicylic acid in the studied doses had a statistically 
significant (p<0.05) positive effect. The greatest effect was 
observed at high doses, reducing CED to 1.69=0.08 c.u. 
and 1.78=0.11 c.u, respectively, but it did not reach the 
target level (Table 1).
In rats with ADMA-like preeclampsia with the ad-
ministration of selective inhibitor of arginase II KUD 
975 at doses of 1 mg/kg/day and 3 mg/kg/day and with 
the administration of acetylsalicylic acid at doses of 7 
mg/kg/day and 10 mg/kg/day, a statistically significant 
(p<0.05) increase in microcirculation in the placenta 
was observed, with the greatest effect at higher doses 
(Table 1).
In rats with ADMA-like preeclampsia, an increase in 
the edema of the greater omentum was observed, which 
resulted in an increase in the fluid content in its tissues 
from 44.39±1.62% to 55.02±1.74%. In addition, there was 
a decrease in the content of final NO metabolites in blood 
plasma from 2.28±0.05 mmol/DL to 1.3±0.02 mmol/DL 
and an increase in proteinuria from 0.23±0.051 g/L to 
2.2±0.177 g/L.
In rats with experimental preeclampsia, there was a 
statistically significant (p<0.05) decrease in fluid content 
in the tissue of the greater omentum when administering 
selective inhibitor of arginase II KUD 975 and acetylsa-
licylic acid in comparison with the group of the untreated 
animals (Fig. 1A). This may indicate a decrease in edema.
A biochemical study of blood plasma revealed a sta-
tistically significant increase in the concentration of final 
NO metabolites in blood plasma under the influence of 
selective inhibitor of arginase II KUD 975 and acetylsali-
cylic acid in the correction of functional disorders in rats 
with ADMA-like preeclampsia (p<0.05) compared with 
the group of the untreated animals (Fig. 1B). The greatest 
effect was observed at high doses (1.93±0.03 µmol/DL 
and 1.75±0.03 µmol/DL, respectively), but the target le-
vel was not achieved.
When ADMA-like agent was administered to the preg-
nant rats from the 14th to the 20th day of pregnancy, there 
was no change in the amount of urine excreted compared 
to the intact pregnant animals; the administration of se-
lective inhibitor of arginase II KUD 975 and low doses 
of acetylsalicylic acid to the rats with experimental pree-
clampsia had no effect on the level of diuresis in experi-
mental animals either (Fig. 1C).
The administration of selective inhibitor of arginase II 
KUD 975 and acetylsalicylic acid to the animals with ex-
perimental preeclampsia caused a statistically significant 
(p<0.05) decrease in protein concentration in urine of the 
experimental animals (Fig. 1D).
The statural-weight values of fetuses in ADMA-like 
preeclampsia and its corrections have to be highlighted. 
The administration of L-NAME led to a decrease in fetu-
ses’ weight and had almost no effect on their growth, so 
there was a statistically significant increase in the height/
weight ratio of the fetuses. With the administration of a 
selective inhibitor of arginase II KUD 975 and acetylsa-
licylic acid, the loss of fetuses’ weights was stopped, ex-
cept in the groups with acetylsalicylic acid at a lower dose 
(Table 2). However, it should be noted that the height-
weight ratio of the fetus is the most accurate indicator, 
since it has a smaller spread. In the groups using selective 
inhibitor of arginase II KUD 975 and acetylsalicylic acid, 
this indicator decreased due to an increase in the weight 
of fetuses, but it did not reach the target level.
Table 1. Results of Correcting ADMA-like Preeclampsia with 
Selective Inhibitor of Arginase II KUD 975 and Acetylsalicylic 
Acid in Rats (M±m; N=10).
Indicator
Group
SBP 
(mmHg)
DBP 
(mmHg)
CED 
(conv.)
Microcircu-
lation (PU)
Intact animals 127.6±1.5y 91.9±5.63y 1.32±0.8y 487.9±22.56y
L-NAME 200.5±6.32* 151±5.69* 3.13±0.21* 210.2±11.18*
L-NAME + L-Norvaline 201.2±6.92* 146.1±5.19* 1.84±0.11*y 345.8±18.25*y
L-NAME + Methyldopa 138.8±3.27*y 99.4±4.36y 2.53±0.18*y 275.3±15.71*y
L-NAME + KUD 975 1 mg/
kg/day
192.7±5.07* 147.1±4.91* 2.02±0.07*y 329.4±17.03*y
L-NAME + KUD 975 3 mg/
kg/day
167.4±4.84*y 126.6±4.85*y 1.69±0.08*y 420.2±13.19*y
L-NAME + ASA 7 mg/
kg/day
198.0±7.53* 146.2±5.19* 2.18±0.10*y 359.4±20.38*y
L-NAME + ASA 10 mg/
kg/day
192.3±7.62* 146.5±4.19* 1.78±0.11*y 414±14.7*y
Notes: SBP – systolic blood pressure (mmHg); DBP – diastolic blood pressure (mmHg); 
CED – coefficient of endothelial dysfunction (c.u.); PU – perfusion units; ASA – acetyl-
salicylic acid; * – p<0.05 compared to the intact animal group; y – p<0.05 compared to 
the L-NAME group.
Table 2. Effect of Selective Inhibitor of Arginase II KUD 975 
and Acetylsalicylic Acid on Fetal Heightand Weight Parameters 
in Rats at ADMA-like Preeclampsia (M±m; n=10).
Indicator
Group
Fetal weight, 
gm
Fetal height, 
mm
Height/weight, 
mm/gm
Intact animals 1.56±0.03y 23.00±0.47 14.77±0.15y
L-NAME 1.44±0.03* 23.3±0.45 16.2±0.13*
L-NAME + L-Norvaline 1.53±0.04 y 23.4±0.52 15.31±0.13y*
L-NAME + Methyldopa 1.53±0.03 y 24.05±0.41 15.74±0.16y*
L-NAME + KUD 975 1 mg/kg/day 1.54±0.03 y 23.5±0.43 15.26±0.13y*
L-NAME + KUD 975 3 mg/kg/day 1.57±0.02 y 23.8±0.41 15.19±0.12y*
L-NAME + ASA 7 mg/kg/day 1.49±0.03 23.4±0.43 15.72±0.16y*
L-NAME + ASA 10 mg/kg/day 1.54±0.03y 23.75±0.48 15.47±0.13y*
Note: * – p<0.05 compared to intact pregnant females; y – p<0.05 compared to L-NAME 
group; ASA – acetylsalicylic acid.
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Figure 1. Effect of selective inhibitor of arginase II KUD 975 and low doses of acetylsalicylic acid on edema of the greater omentum 
(A), the content of final nitric oxide metabolites in plasma (B), diuresis (C) and proteinuria (D) in rats at ADMA-like preeclampsia. 
Note: * – p<0.05 compared to intact pregnant females; y – p<0.05 compared to L-NAME group; ASA – acetylsalicylic acid.
Experimental study of the effect of combined use 
of selective inhibitor of arginase II KUD 975 with 
acetylsalicylic acid on functional disorders in ADMA-
like preeclampsia
When selective inhibitor of arginase II KUD 975 is ad-
ministered in combination with acetylsalicylic acid (a 
drug included in the standard regimen of the preven-
tive therapy of hypertensive states and preeclampsia 
in pregnant women) to the rats with experimental AD-
MA-like preeclampsia, there was a statistically signifi-
cant (p<0.05) decrease in systolic and diastolic blood 
pressure (166.5±6.5 mmHg and 123.6±6.8 mmHg, 
respectively) in comparison with the group of the un-
treated rats, but the target level could not be achieved 
(Table 3).
The ratio of endothelium-dependent vasorelaxation 
and endothelium-independent vasorelaxation, expresse 
by CED, was positively affected by the combined admi-
nistration of selective inhibitor of arginase II KUD 975 
and acetylsalicylic acid to the rats with experimental pree-
clampsia, which was expressed in reaching a level statisti-
cally indistinguishable from the level of the intact animals 
(1.39±0.1 c.u. (Table 3).
In the rats with experimental preeclampsia, the com-
bined administration of selective inhibitor of arginase II 
KUD 975 and acetylsalicylic acid resulted in a statistical-
ly significant (p<0.05) increase in microcirculation in the 
placenta (478.4±13.3 PU), which reached the level of the 
intact animals (Table 3).
The study of the concentration of final metabolites of 
nitric oxide in blood plasma when administering selective 
inhibitor of arginase II KUD 975 with acetylsalicylic acid 
to the rats with ADMA-like preeclampsia revealed their 
statistically significant(p<0.05) increase to the level of the 
intact animals (Fig. 2A).
The study of the content of fluid in the tissues of the 
greater omentum in the rats with experimental pree-
clampsia revealed that there was a statistically significant 
(p<0.05) decrease of this indicator when administering 
selective inhibitor of arginase II KUD 975 in combination 
with acetylsalicylic acid (45.28±1.96%), compared to the 
group of the untreated rats, with this indicator achieving 
the level of the intact animals (Fig. 2B).
Table 3. Results of Correction of ADMA-like Preeclampsia in 
Rats by Combined Administration of Selective Inhibitor of Ar-
ginase II KUD 975 and ASA (M±m; N=10).
Indicator
Group
SBP 
(mmHg)
DBP 
(mmHg)
CED 
(conv.)
Microcirculation 
(PU)
Intact animals 127.6±1.5 y 95.36±2.82y 1.32±0.8y 487.9±22.56y
L-NAME 200.5±6.32* 151±5.69* 3.13±0.21* 210.2±11.18*
L-NAME + KUD 975 
3 mg/kg/day
167.4±4.84*y 126.6±4.85*y 1.69±0.08*y 420.2±13.19y*
L-NAME + ASA 10 mg/
kg/day
192.3±7.62* 146.5±4.19* 1.78±0.11*y 414±14.7*y
L-NAME + KUD 975 
3 mg/kg/day + ASA 
10 mg/kg/day
166.5±6.5*y 123.6±6.8*y 1.39±0.1y 478.4±13.3y
Notes: SBP – systolic blood pressure (mmHg); DBP – diastolic blood pressure (mmHg); 
CED – coefficient of endothelial dysfunction (c.u.); PU – perfusion units; ASA – acetyl-
salicylic acid; * – p<0.05 compared to the intact animal group; y – p<0.05 compared to 
the L-NAME group.
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Figure 2. Effect of combined administration of selective inhibitor of arginase II KUD 975 with a low dose of acetylsalicylic acid 
on the content of final metabolites of nitric oxide in plasma (A), edema of the greater omentum (B), diuresis (C) and proteinuria 
(D) of rats in ADMA-like preeclampsia. Note: * – p<0.05 compared to intact pregnant females; y – p<0.05 compared to the 
L-NAME group.
The combined administration of selective inhibitor of 
arginase II KUD 975 in combination with acetylsalicylic 
acid to the rats with experimental preeclampsia results in 
a decrease in proteinuria to 0.79±0.1 g/L, which is statis-
tically indistinguishable from the level of the intact ani-
mals (Fig. 2D). There was no effect on the level of diure-
sis (Fig. 2).
The study of the results of correction of height-weight 
parameters in the fetuses in experimental preeclampsia 
revealed the following pattern. The combined administra-
tion of selective inhibitor of arginase II KUD 975 and ace-
tylsalicylic acid resulted in stopping the featuses’ weight 
loss (Table 4). At the same time it should be noted that 
the ratio of height and weight of the fetus approached the 
level of statistically indistinguishable from the level of 
intact rats.
Experimental study of the effect of the combination of 
acetylsalicylic acid and selective inhibitor of arginase 
II KUD 975 with methyldopa on functional disorders 
and height-weight parameters of fetuses in ADMA-li-
ke preeclampsia
The administration of acetylsalicylic acid and selective 
inhibitor of arginase II KUD 975 in combination with 
methyldopa to the rats with experimental preeclamp-
sia led to a statistically significant (p<0.05) decrease in 
systolic and diastolic blood pressure levels, reaching the 
levels of those in the animals with physiological preg-
nancy at 131.0±2.0 mmHg and 92.4±2.8 mmHg, respec-
tively, and 127.3±1.5 mmHg and 88.3±2.1 mmHg, res-
pectively (Table 5).
The study of the ratio of endothelium-dependent vaso-
relaxation and endothelium-independent vasorelaxation, 
the expression of which is CED, showed that the admi-
nistration of acetylsalicylic acid and selective inhibitor 
of arginase II KUD 975 in combination with methyldopa 
Table 4. Effect of Combined Use of Selective Inhibitor of Argin-
ase II KUD 975 with Acetylsalicylic Acid on Height and Weight 
Parameters of Fetal Development in Rats with ADMA-like Pre-
eclampsia (M=m; n=10).
Indicator
Group
Fetal weight, 
gm
Fetal height, 
mm
Height/weight, 
mm/gm
Intact animals 1.56±0.0y 23.00±0.47 14.77±0.15y
L-NAME 1.44±0.0* 23.3±0.45 16.22±0.13y
L-NAME + KUD 975 3 mg/kg/day 1.57±0.02y 23.8±0.41 15.19±0.12*y
L-NAME + ASA 10 mg/kg/day 1.54±0.03y 23.75±0.48 15.47±0.13*y
L-NAME + KUD 975 3 mg/kg/day 
+ ASA 10 mg/kg/day
1.57±0.04y 23.4±0.55 14.91±0.10y
Note: * – p<0.05 compared to the intact animal group; y – p<0.05 compared to the 
L-NAME group; ASA – acetylsalicylic acid.
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to the rats with experimental preeclampsia had a positive 
effect, statistically significantly (p<0.05) reducing this ra-
tio to the level of the intact animals (1.51±0.1 c.u. and 
1.41±0.1 c.u., respectively) (Table 5).
In the rats with ADMA-like preeclampsia, the admi-
nistration of acetylsalicylic acid and selective inhibitor 
of arginase II KUD 975 in combination with methyldopa 
resulted in a statistically significant (p<0.05) increase in 
microcirculation in the placenta, reaching the level of that 
in the intact animals at 469.8±15.44 PU and 483.0±14.20 
PU, respectively (Table 5).
Evaluation of the fluid content in the tissues of the gre-
ater omentum revealed a statistically significant (p<0.05) 
decrease in this indicator when administrating acetylsa-
licylic acid and selective inhibitor of arginase II KUD 
975 in combination with methyldopa to the rats with ex-
perimental preeclampsia in comparison with the group 
of the untreated animals, to the level of 44.32±2.1% and 
44.65±1.67%, respectively. It should be noted that the 
edema index reached the level of that in the intact rats 
(Fig. 3A).
The biochemical study of the concentration of final 
metabolites of nitric oxide in blood plasma with the ad-
ministration of acetylsalicylic acid and selective inhibitor 
of arginase II KUD 975 in combination with methyldopa 
to the rats with ADMA-like preeclampsia revealed their 
statistically significant (p<0.05) increase, to a level sta-
tistically indistinguishable from the level that in the intact 
animals (Fig. 3B).
When acetylsalicylic acid and selective inhibitor of 
arginase II KUD 975 are administered in combination 
with methyldopa to the rats with ADMA-like preeclamp-
sia, there was a statistically significant (p<0.05) decrease 
in proteinuria, which reached the level in the intact rats 
(0.33±0.09 g/L and 0.38±0.09 g/L) (Fig. 3D). No effect on 
Table 5. Results of Correction of ADMA-like Preeclampsia by 
Administration of Acetylsalicylic Acid and Selective Inhibitor 
of Arginase II KUD 975 in Combination with Methyldopa to 
Rats (M±m; N=10).
Indicator
Group
SBP 
(mmHg)
DBP 
(mmHg)
CED 
(conv.)
Microcirculation 
(PU)
Intact animals 127.6±1.5y 91.9±5.63y 1.32±0.8y 487.9±22.56y
L-NAME 200.5±6.32* 151±5.69* 3.13±0.21* 210.2±11.18*
L-NAME + Methyldopa 
0.043 g/kg x 2 times/day
138.8±3.27*y 99.4±4.36y 1.84±0.11* y 345.8±18.25*y
L-NAME + ASA 10 mg/
kg/ day
192.7±5.07* 147.1±4.91* 2.02±0.07*y 329.4±17.03*y
L-NAME + KUD 975 3 
mg/kg/day
167.4±4.84*y 126.6±4.85*y 1.69±0.08*y 420.2±13.19*y
L-NAME + ASA 10 mg/
kg/day + Methyldopa 
0.043 g/kg x 2 times/day
131.0±2.0y 92.4±2.8y 1.51±0.1y 469.8±15.44y
L-NAME + KUD 975 3 
mg/kg/day + Methyldopa 
0.043 g/kg x 2 times /day
127.3±1.5y 88.3±2.1y 1.41±0.1y 483.0±14.20y
Notes: SBP – systolic blood pressure (mmHg); DBP – diastolic blood pressure (mmHg); 
CED – coefficient of endothelial dysfunction (c.u.); PU – perfusion units; ASA – acetyl-
salicylic acid; * – p<0.05 compared to the intact animal group; y – <0.05 compared to 
the L-NAME group.
A B
C D
Figure 3. The impact of the administration of a low dose of acetylsalicylic acid and selective inhibitor of arginase II KUD 975 and 
their combinations with methyldopa on the content of final nitric oxide metabolites in plasma (A), edema of the greater omentum 
(B), diuresis (C), and proteinuria (D) in rats with ADMA-like preeclampsia. Note: * – p<0.05 compared to intact pregnant 
females; y – p<0.05 compared to L-NAME group; ASA – acetylsalicylic acid.
Severinova OV et al.: Study of  the effect of  selective inhibitor of  Arginase II KUD 975...54
the level of diuresis in the experimental rats was recorded 
(Fig. 3).
The study of the results of correcting the height and 
weight parameters in fetuses in experimental pree-
clampsia showed an increase in fetal body weight in 
the groups with combined use of selective inhibitor 
of arginase II KUD 975 and acetylsalicylic acid with 
methyldopa (Table 6). It should be noted that the ratio 
of height and weight of the fetus approached the level 
which was statistically indistinguishable from the level 
in the intact rats.
Summing up all the above, it can be argued that 
the results of the series of experiments indicate a 
pronounced protective activity of selective inhibitor 
of arginase II KUD 975 and low doses of ASA in the 
correction of morpho-functional disorders in ADMA-
like preeclampsia.
The positive effects of selective inhibitor of argina-
se II KUD 975 in the correction of morpho-functional 
disorders in ADMA-like preeclampsia can be explained 
by the available literature data on the ability of arginase 
II inhibitors to prevent the conversion of L-arginine into 
ornithine and urea, resulting in the formation of a larger 
amount of nitric oxide from L-arginine under the acti-
on of NO-synthase (Dzugkoev et al. 2018, Gewaltig and 
Kojda 2002, Miller 2006). The increased production of 
NO reduces the signs of endothelial dysfunction and con-
tributes to the normalization of the regulatory mechanis-
ms of the vascular tone. Elimination of vasoconstriction 
leads not only to lower blood pressure, but also improves 
tissue trophism, relieving ischemic symptoms in them, 
including in the placenta. Thus, by reducing the release 
of humoral factors of ischemic origin by the placenta, the 
vicious circle was broken, in which placental ischemia 
contributed to endothelial dysfunction, and endothelial 
dysfunction caused placental ischemia (Rodger et al. 
2014). In support of the above, the previously published 
data on the efficacy of nonselective inhibitor of arginase 
II L-Norvaline in the correction of morpho-functional di-
sorders in ADMA-like preeclampsia can be cited.
The positive effects of aspirin are related to its ability 
to irreversibly inhibit cyclooxygenase 1 (COX 1) of plate-
lets (AlSheeha et al. 2016, Khodzhaeva et al. 2018). This 
reduces the formation of thromboxane A2, which causes 
vasoconstriction and activation of platelet adhesion and 
aggregation. Thus, acetylsalicylic acid by inhibiting the 
synthesis of thromboxane A2 reduces platelet activation 
(Sahin et al. 2015).
In the literature, there are data on the ability of low 
doses of acetylsalicylic acid to promote an increase in 
placental vascularization, normalization of the balance of 
angiogenic growth factors, such as VEGF, sVEGFR-1, 
PlGF in the serum of pregnant women. In addition, low 
doses of aspirin help improve the depth of placentation, 
microcirculation in the placenta and increase the blood 
flow in the spiral uterine arteries (Adamyan et al. 2016, 
Roberge et al. 2012, Roberge et al. 2016). Thus, the 
mechanisms of positive effects of acetylsalicylic acid in-
clude the improvement of microcirculation in tissues, re-
duction of thrombotic conditions and optimization of ne-
ovasculogenesis in the placenta. This leads to a decrease 
in ischemic conditions in the placenta and the restoration 
of the endothelial function, which play an important role 
in the modern understanding of the pathogenetic mecha-
nisms of preeclampsia.
The most pronounced effects are observed with the 
combined use of the studied pharmacological agents. 
This can be explained by the fact that having different 
mechanisms of action, the studied pharmacological 
agents affect a greater number of pathogenetic links of 
the developing pathology.
Conclusion
1. Selective inhibitor of arginase II KUD 975 has a 
pronounced protective activity in the correction of 
morpho-functional disorders arising in the simulat-
ed ADMA-like preeclampsia.
2. Acetylsalicylic acid in low doses exhibits protec-
tive properties in the correction of morpho-func-
tional disorders arising from ADMA-like pre-
eclampsia in rats.
3. The use of methyldopa in combination with a se-
lective inhibitor of arginase II KUD 975 and ace-
tylsalicylic acid leads to an increase in their posi-
tive effects in the correction of morpho-functional 
disorders occurring in ADMA-like preeclampsia 
in rats.
4. Selective inhibitor of arginase II KUD 975 in com-
bination with low doses of acetylsalicylic acid ex-
hibits more pronounced protective properties com-
pared to a mono therapy.
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Table 6. Effect of Combined Use of Selective Inhibitor of Ar-
ginase II KUD 975 with a Low Dose of Acetylsalicylic Acid 
and Their Combination with Methyldopa on Height and Weight 
Parameters of Fetal Development in Rats with ADMA-like Pre-
eclampsia (M±m; n=10).
Indicator
Group
Fetal weight, 
gm
Fetal height, 
mm
Height/weight, 
mm/gm
Intact animals 1.56±0.03y 23.00±0.47 14.77±0.15y
L-NAME 1.44±0.03* 23.3±0.45 16.22±0.13*
L-NAME + KUD 975 3 mg/kg/day 1.57±0.02y 23.8±0.41 15.19±0.12*y
L-NAME + ASA 10 mg/kg/day 1.54±0.03y 23.75±0.48 15.47±0.13*y
L-NAME+ KUD 975 3 mg/kg/day + 
Methyldopa 0.043 g/kg x 2 times /day
1.57±0.04y 23.3±0.50 14.81±0.11y
L-NAME+ ASA 10 mg/kg/day + 
Methyldopa 0.043 g/kg x 2 times /day
1.6±0.04y 23.65±0.54 17.86±0.11y
Note: * – p<0.05 compared to the intact animal group; y – p<0.05 compared to the 
L-NAME group; ASA – acetylsalicylic acid.
Research Results in Pharmacology 5(4): 47–56 55
References
  Adamyan LV, Artymuk NV, Bashmakova NV, Belokrinitskaya TE 
(2016) Hypertension During Pregnancy, Childbirth and the Postpar-
tum Period. Preeclampsia and Eclampsia (Clinical protocols). Mos-
cow, 72 pp. [in Russian]
  AlSheeha MA, Alaboudi RS, Alghasham MA, Iqbal J, Adam I 
(2016) Platelet count and platelet indices in women with preeclamp-
sia. Vascular Health and Risk Management 12: 477–480. https://doi.
org/10.2147/VHRM.S120944 [PubMed] [PMC]
  Blomqvist LRF, Strandell AM, Baghaei F, Hellgren MSE (2019) 
Platelet aggregation in healthy women during normal pregnancy – a 
longitudinal study. Platelets 30(4): 438–444. https://doi.org/10.1080
/09537104.2018.1492106 [PubMed]
  Dzugkoev SG, Dzugkoeva FS, Margieva OI, Mozhaeva IV (2018) 
Correction of endothelial dysfunction in Nickel intoxication with in-
hibitors of ENOS and arginase in the experiment. Modern Problems 
of Science and Education [Sovremennyye Problemy Nauki i Obrazo-
vaniya] 4: 1–175. https://doi.org/10.17513/spno.27787 [in Russian]
  Elagin VV, Bratchikov OI, Ulyanova AA (2018) Approaches to cor-
rection of ischemic and reperfusion kidney injuries in experiment. 
Research Results in Biomedicine [Nauchnyye Rezul’taty Biomed-
itsinskikh Issledovaniy] 4(3): 63–69. https://doi.org/10.18413/2313-
8955-2018-4-3-0-6 [in Russian]
  Gewaltig MT, Kojda G (2002) Vasoprotection by nitric oxide: mech-
anisms and therapeutic potential. Cardiovascular Research 55(2): 
205–260. https://doi.org/10.1016/S0008-6363(02)00327-9 [PubMed]
  Gureev VV, Alehin SA, Pokrovskiy MV, Dolghikov AA, Korokin 
MV, Gudyrev OS, Kolesnik IM (2014) Remote ischemic precondi-
tioning correction in ADMA-like gestosis model. Research Journal of 
Pharmaceutical, Biological and Chemical Sciences 5(5): 1095–1098.
  Gureev VV, Pokrovskii MV, Korokin MV, Gudyrev OS, Philippova 
OV, Dolzhikov AA, Lazareva GA (2015) Correction of ADMA-in-
duced preeclampsia with use of tetrahydrobiopterin and selective in-
hibitor of arginase II ZB49-0010. Research Journal of Pharmaceuti-
cal, Biological and Chemical Sciences 6(5): 1538–1541. https://doi.
org/10.18413/2313-8955-2015-1-4-66-68
  Hussien NI, Emam HT (2016) The potential protective effects of 
erythropoietin and estrogen on renal ischemia reperfusion injury in 
ovariectomized rats. Alexandria Journal of Medicine 52(4): 325–
335. https://doi.org/10.1016/j.ajme.2015.12.001
  Khodzhaeva ZS, Kholin AM, Chulkov VS, Muminova KT (2018) 
Acetylsalicylic acid in the prevention of preeclampsia and associat-
ed obstetric and perinatal complications. Obstetrics and Gynecolo-
gy [Akusherstvo i Ginekologiya] 8: 8–12. https://doi.org/10.18565/
aig.2018.8.12-18 [in Russian]
  Korokin MV, Pokrovskii MV, Gudyrev OS, Korokina LV, 
Pokrovskaia TG, Lazarev AI, Philippenko NG, Gureev VV (2015) 
Pharmacological correction of endothelial dysfunction in rats using 
e-NOS cofactors. Research Journal of Pharmaceutical, Biological 
and Chemical Sciences 6(5): 1548–1552.
  Makarenko MV (2014) Systemic production of cytokines and 
growth factors in various forms of syndrome of delayed fetal growth. 
Klinichna Khirurhiia 11: 67–70. [PubMed]
  Memmert S, Gölz L, Pütz P, Jäger A, Deschner J, Appel T, Baumgar-
ten G, Rath-Deschner B, Frede S, Götz W (2016) Regulation of p53 
under hypoxic and inflammatory conditions in periodontium. Clin-
ical Oral Investigations 20(7): 1781–1789. https://doi.org/10.1007/
s00784-015-1679-x [PubMed]
  Miller AL (2006) The effects of sustained-release-L-arginine formu-
lation on blood pressure and vascular compliance in 29 healthy indi-
viduals. Alternative Medicine Review: a Journal of Clinical Thera-
peutic 11(1): 23–29. [PubMed]
  Pokrovskiy MV, Pokrovskaia TG, Gureev VV, Barsuk AA, Pro-
skuriakova EV, Korokin MV, Gudyrev OS, Belous AS, Kochkarov 
VI, Danilenko LM, Levashova OV, Mal’tseva NV, Polianskaia OS 
(2012) Correction of endothelial dysfunction by L-arginine under 
experimental pre-eclampsia conditions. Experimental and Clinical 
Pharmacology [Eksperimental’naia i Klinicheskaia Farmakologiia] 
75(2): 14–16. [PubMed]
  Roberge S, Odibo AO, Bujold E (2016) Aspirin for the Preven-
tion of Preeclampsia and Intrauterine Growth Restriction. Clinics 
in Laboratory Medicine 36(2): 319–329. https://doi.org/10.1016/j.
cll.2016.01.013 [PubMed]
  Roberge S, Villa P, Nicolaides K, Giguère Y, Vainio M, Bakthi A, 
Ebrashy A, Bujold E (2012) Early administration of low-dose aspirin 
for the prevention of preterm and term preeclampsia: a systematic 
review and meta-analysis. Fetal Diagnosis and Therapy 31(3): 141–
146. https://doi.org/10.1159/000336662 [PubMed]
  Rodger MA, Carrier M, Le Gal G, Martinelli I, Perna A, Rey E, 
de Vries JIP, Gris JC on behalf of the Low-Molecular-Weight Hep-
arin for Placenta-Mediated Pregnancy Complications Study Group 
(2014) Meta-analysis of low-molecular-weight heparin to prevent re-
current placenta-mediated pregnancy complications. Blood 123(6): 
822–828. https://doi.org/10.1182/blood-2013-01-478958 [PubMed]
  Sahin S, Ozakpinar OB, Eroglu M, Tulunay A, Ciraci E, Uras F, 
Tetik S (2015) The impact of platelet functions and inflammatory 
status on the severity of preeclampsia. Journal of Maternal-fetal and 
Neonatal Medicine 28(6): 643–648. https://doi.org/10.3109/147670
58.2014.927860 [PubMed]
  Saito S, Sakai M, Sasaki Y, Nakashima A, Shiozaki A (2007) Inade-
quate tolerance induction may induce pre-eclampsia. Journal of Re-
productive Immunology 76(1–2): 30–39. https://doi.org/10.1016/j.
jri.2007.08.002 [PubMed]
  Severinova OV, Lokteva TI, Gureev VV, Zhernakova NI, Osipova 
OA, Dolzhikov AA, Pokrovskaya TG (2019) The effect of arginase 
II selective inhibitors on the functional parameters of experimental 
animals in ADMA-like preeclampsia. Journal of International Phar-
maceutical Research 46(4): 272–275.
  Shakhno E, Savitskaya T, Pokrovskaya T, Yakushev V, Pokrovsky 
M, Grinshpan D (2016) Use of Larginine immobilised on activated 
carbon for pharmacological correction of endothelial disfunction. 
Research Result: Pharmacology and Clinical Pharmacology 2(1): 
30–35. https://doi.org/10.18413/2313-8971-2016-2-1-30-35
  Sidorenko VN, Mazhul VM, Chernovets TS (2007) Molecular mem-
brane mechanisms of dysfunction of activity and protease-induced 
platelet aggregation in pregnancy complicated by gestosis. Journal 
of Grodno State Medical University [Zhurnal GrGMU] 2: 35–38. 
[in Russian]
  Skachilova SYa, Kotelnikova AS, Timokhina AS, Shcheblykina OV 
(2018) Evaluation of antihypoxic activity of ethylmethylhydroxipyri-
dine sukcinate in in vitro experiments. Research Results in Biomedi-
Severinova OV et al.: Study of  the effect of  selective inhibitor of  Arginase II KUD 975...56
cine [Nauchnyye Rezul’taty Biomeditsinskikh Issledovaniy] 4(3): 70–
75. https://doi.org/10.18413/2313-8955-2018-4-3-0-7 [In Russian].
  Tyurenkov IN, Ivanova LB, Karamysheva VI, Lebedeva SA (2012) 
Correction of hemostatic disorders in females with experimental 
gestosis using GABA derivatives. Journal of Obstetrics and Wom-
en’s Diseases [Zhurnal Akusherstva i Zhenskikh Bolezney] 61(4): 
119–123. https://doi.org/10.17816/JOWD614119-123 [in Russian]
  Xu C, Li X, Guo P, Wang J (2017) Hypoxia-induced activation of 
JAK/STAT3 signaling pathway promotes trophoblast cell viabili-
ty and angiogenesis in preeclampsia. Medical Science Monitor 23: 
4909–4917. https://doi.org/10.12659/MSM.905418 [PubMed] [PMC]
  Yakushev VI, Filippenko NG, Kizilova IV (2016) Research of dose-de-
pendent endothelioprotective and cardioprotective activity of selective 
arginase II inhibitor in homocysteine-induced endothelial dysfunction. 
Research Result: Pharmacology and Clinical Pharmacology 2 (1): 42–
45. https://doi.org/10.18413/2313-8971-2016-2-1-42-45
  Yakushev VI, Pokrovsky MV, Korokin MV, Pokrovskaya TG, Ku-
likovskaya VD, Ershov IN, Beskhmelnitsyna EA, Arustamova AA, 
Kotelnikova LV (2012) Arginase – a new target for the pharmacolog-
ical correction of endothelial dysfunction. Research Bulletin of Bel-
gorod State University. Series: Medicine. Pharmacia [Nauchnyye Ve-
domosti. Seriya: Meditsina. Farmatsiya] 22 (141): 36–40. [in Russian]
Author’s Contributors
  Olga V. Severinova, postgraduate student, Department of Pharmacology and Clinical Pharmacology, e-mail: fren-
dic@mail.ru. ORCID: http://orcid.org/0000-0003-3873-0773. The author had a leading role in planning and per-
forming the experiment, analyzing the data and literature and writing the article.
  Vladimir V. Gureev Doctor of Medical Sciences, Associate Professor, Professor of the Department of Pharmaco-
logy and Clinical Pharmacology, e-mail: produmen@mail.ru. ORCID: http://orcid.org/0000-0003-1433-1225. The 
author took part in planning experiments, analyzed the literature and participated in interpreting the data.
  Lyudmila A. Zhilinkova, PhD in Technical Sciences, Associate Professor, Department of Philosophy, Social, 
Legal and Natural Sciences, e-mail: l_zhilinkova@mail.ru., ORCID: http://orcid.org/0000-0003-0443-7130. The 
author took part in planning experiments, analyzed the literature and participated in interpreting the data.
  Galina A. Lazareva, Doctor of Medical Sciences, Professor, Head of the Department of Obstetrics and Gynae-
cology, e-mail: akush.fpo@gmail.com, ORCID: http://orcid.org/0000-0002-1225-8039. The author took part in 
planning experiments, analyzed the literature and participated in interpreting the data.
  Anastasia V. Gureeva, 3 year student, Faculty of Medicine, e-mail: nastasyi.207@gmail.com. The author took part 
in planning experiments, analyzed the literature and participated in interpreting the data.
  Sofia S. Lazareva 3 year student, Faculty of Medicine, e-mail: sophie_lazareva31@mail.ru. ORCID: http://orcid.
org/0000-0003-1132-6594. The author took part in planning experiments, analyzed the literature and participated 
in interpreting the data.
